Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR-T cell therapy in India: VELCART trial

Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR-T cell therapy in India: VELCART trial

Decentralized or point-of-care (POC) manufacture of CAR-T cells is a potential strategy to improve accessibility and reduce cost and logistic challenges. A total of 10 relapsed/refractory patients (B cell acute lymphoblastic leukemia [B-ALL] N = 6, diffuse large B cell lymphoma [DLBCL] N = 4) were e...

Full description

Saved in:
Bibliographic Details
Main Authors: Hamenth Kumar Palani, Arun Kumar Arunachalam, Uday Kulkarni, Mohammed Yasar, Arvind Venkatraman, Swathy Palanikumar, Reeshma Nair Radhakrishnan, Majeela Solomon, Abirami Rajasekaran, Aniket Bankar, Phaneendra Venkateswara Rao Datari, Sushil Selvarajan, Anu Korula, Pradyot Dash, Dina Schneider, Louisa Wirthlin, Aby Abraham, Biju George, Vikram Mathews
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Molecular Therapy: Oncology
Subjects:
MT: Regular Issue
CART-cell therapy
point-of-care manufacturing
CliniMACS Prodigy
cost analysis
decentralized manufacturing
Online Access:http://www.sciencedirect.com/science/article/pii/S2950329925000463
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2950329925000463

Similar Items